Previous 10 | Next 10 |
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Gorlin Syndrome KOL event to be held on December 6, 2023 Sol-Gel maintains cash runway into the second half of 2025 NESS ZIONA, Israel, Nov. 09, 202...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Sol-Gel Technologies Ltd. (SLGL) is expected to report $-0.23 for Q3 2023
2023-10-06 13:29:08 ET Gainers: Falcon's Beyond Global (FBYD) +145% . American Oncology Network ( AONC ) +53% . Akso Health Group ( AHG ) +23% . Vigil Neuroscience ( VIGL ) +20% . NuScale Power Corporation ( SMR )...
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and...
2023-08-10 12:22:30 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q2 GAAP EPS of -$0.24 beats by $0.02 . As of June 30, 2023, Sol-Gel had $29.1 million in cash, cash equivalents and deposits, and $17.9 million in marketable securities for a total balance of $...
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently announced agreement with Searchlight Pharma will provide up to $11 million in upfront payments and regulatory and sales milestones for...
2023-06-06 12:42:07 ET Israel's Sol-Gel ( NASDAQ: SLGL ) has signed an exclusive licensing deal with Searchlight Pharma for the Canadian commercialization rights to its dermatology products Twyneo and Eposolay. Sol-Gel said it will receive up to $11M in upfront and milestone...
Sol-Gel to receive up to $11 million in upfront payment s and regulatory and sales milestone s for both drugs, combined, plus additional royalties ranging from low double-digits to high - teens Non -di lutive capital stre...
2023-05-12 07:31:54 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q1 GAAP EPS of -$0.41. Revenue of $0.76M. As of March 31, 2023, Sol-Gel had $20.3 million in cash, cash equivalents and deposits, and $18.4 million in marketable securities for a total balance ...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...